Aarhus University Seal / Aarhus Universitets segl

Sleep disruption and Alzheimer's disease risk: Inferences from men with benign prostatic hyperplasia:

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaperJournal articleResearchpeer-review

Standard

Sleep disruption and Alzheimer's disease risk : Inferences from men with benign prostatic hyperplasia: / Nørgaard, Mette; Horváth-Puhó, Erzsébet; Corraini, Priscila; Sørensen, Henrik Toft; Henderson, Victor W.

In: EClinicalMedicine, Vol. 32, 100740, 02.2021.

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaperJournal articleResearchpeer-review

Harvard

APA

CBE

MLA

Vancouver

Author

Bibtex

@article{23de0f08c0a24e1bab60e758678ae60b,
title = "Sleep disruption and Alzheimer's disease risk: Inferences from men with benign prostatic hyperplasia:",
abstract = "Background: Sleep disturbances may increase risks of Alzheimer's disease (AD) and other dementias. Benign prostatic hyperplasia (BPH) is usually associated with lower urinary tract symptoms, including nocturia, and thereby disturbed sleep. We examined if men with BPH are at increased risk of AD and all-cause dementia. Methods: In a Danish nationwide cohort (1996–2016), we identified 297,026 men with BPH, defined by inpatient or outpatient hospital diagnosis or by BPH-related surgical or medical treatment, and 1,107,176 men from the general population matched by birth year. We computed rates, cumulative incidences, and adjusted hazard ratios (HRs) of AD and all-cause dementia. Follow-up started 1 year after BPH diagnosis date/index date. Findings: Median follow-up was 6·9 years (Interquartile range (IQR), 3·6 – 11·6 years] in the BPH cohort and 6·4 years (IQR: 3·4 – 10·8 years) in the comparison cohort. The cumulative 1–10 year risk of AD was 1·15% [95% confidence interval (CI), 1·11–1·20], in the BPH cohort and 1·00% (95% CI, 0·98 – 1·02) in the comparison cohort. The adjusted 1–10–year hazard ratios were 1·16 (95% CI: 1·10–1·21) for AD and 1·21 (95% CI: 1·17–1·25) for all-cause dementia. From >10 years up to 21 years of follow-up, BPH remained associated with 10%- 20% increased risk of AD and all-cause dementia. Interpretation: During up to 21 years of follow-up, men with BPH had persistently higher risk of AD and all-cause dementia compared with men in the general population. Our results identify BPH as a common, potentially remediable disorder associated with dementia risk. Funding: Lundbeckfonden, Aarhus University Research Foundation, and the National Institutes of Health.",
keywords = "Alzheimer's disease, Benign prostatic hyperplasia, Dementia, Lower urinary tract symptoms, Nationwide cohort study",
author = "Mette N{\o}rgaard and Erzs{\'e}bet Horv{\'a}th-Puh{\'o} and Priscila Corraini and S{\o}rensen, {Henrik Toft} and Henderson, {Victor W.}",
note = "Publisher Copyright: {\textcopyright} 2021 The Authors",
year = "2021",
month = feb,
doi = "10.1016/j.eclinm.2021.100740",
language = "English",
volume = "32",
journal = "EClinicalMedicine",
issn = "2589-5370",
publisher = "The Lancet Publishing Group",

}

RIS

TY - JOUR

T1 - Sleep disruption and Alzheimer's disease risk

T2 - Inferences from men with benign prostatic hyperplasia:

AU - Nørgaard, Mette

AU - Horváth-Puhó, Erzsébet

AU - Corraini, Priscila

AU - Sørensen, Henrik Toft

AU - Henderson, Victor W.

N1 - Publisher Copyright: © 2021 The Authors

PY - 2021/2

Y1 - 2021/2

N2 - Background: Sleep disturbances may increase risks of Alzheimer's disease (AD) and other dementias. Benign prostatic hyperplasia (BPH) is usually associated with lower urinary tract symptoms, including nocturia, and thereby disturbed sleep. We examined if men with BPH are at increased risk of AD and all-cause dementia. Methods: In a Danish nationwide cohort (1996–2016), we identified 297,026 men with BPH, defined by inpatient or outpatient hospital diagnosis or by BPH-related surgical or medical treatment, and 1,107,176 men from the general population matched by birth year. We computed rates, cumulative incidences, and adjusted hazard ratios (HRs) of AD and all-cause dementia. Follow-up started 1 year after BPH diagnosis date/index date. Findings: Median follow-up was 6·9 years (Interquartile range (IQR), 3·6 – 11·6 years] in the BPH cohort and 6·4 years (IQR: 3·4 – 10·8 years) in the comparison cohort. The cumulative 1–10 year risk of AD was 1·15% [95% confidence interval (CI), 1·11–1·20], in the BPH cohort and 1·00% (95% CI, 0·98 – 1·02) in the comparison cohort. The adjusted 1–10–year hazard ratios were 1·16 (95% CI: 1·10–1·21) for AD and 1·21 (95% CI: 1·17–1·25) for all-cause dementia. From >10 years up to 21 years of follow-up, BPH remained associated with 10%- 20% increased risk of AD and all-cause dementia. Interpretation: During up to 21 years of follow-up, men with BPH had persistently higher risk of AD and all-cause dementia compared with men in the general population. Our results identify BPH as a common, potentially remediable disorder associated with dementia risk. Funding: Lundbeckfonden, Aarhus University Research Foundation, and the National Institutes of Health.

AB - Background: Sleep disturbances may increase risks of Alzheimer's disease (AD) and other dementias. Benign prostatic hyperplasia (BPH) is usually associated with lower urinary tract symptoms, including nocturia, and thereby disturbed sleep. We examined if men with BPH are at increased risk of AD and all-cause dementia. Methods: In a Danish nationwide cohort (1996–2016), we identified 297,026 men with BPH, defined by inpatient or outpatient hospital diagnosis or by BPH-related surgical or medical treatment, and 1,107,176 men from the general population matched by birth year. We computed rates, cumulative incidences, and adjusted hazard ratios (HRs) of AD and all-cause dementia. Follow-up started 1 year after BPH diagnosis date/index date. Findings: Median follow-up was 6·9 years (Interquartile range (IQR), 3·6 – 11·6 years] in the BPH cohort and 6·4 years (IQR: 3·4 – 10·8 years) in the comparison cohort. The cumulative 1–10 year risk of AD was 1·15% [95% confidence interval (CI), 1·11–1·20], in the BPH cohort and 1·00% (95% CI, 0·98 – 1·02) in the comparison cohort. The adjusted 1–10–year hazard ratios were 1·16 (95% CI: 1·10–1·21) for AD and 1·21 (95% CI: 1·17–1·25) for all-cause dementia. From >10 years up to 21 years of follow-up, BPH remained associated with 10%- 20% increased risk of AD and all-cause dementia. Interpretation: During up to 21 years of follow-up, men with BPH had persistently higher risk of AD and all-cause dementia compared with men in the general population. Our results identify BPH as a common, potentially remediable disorder associated with dementia risk. Funding: Lundbeckfonden, Aarhus University Research Foundation, and the National Institutes of Health.

KW - Alzheimer's disease

KW - Benign prostatic hyperplasia

KW - Dementia

KW - Lower urinary tract symptoms

KW - Nationwide cohort study

UR - http://www.scopus.com/inward/record.url?scp=85100444600&partnerID=8YFLogxK

U2 - 10.1016/j.eclinm.2021.100740

DO - 10.1016/j.eclinm.2021.100740

M3 - Journal article

C2 - 33681742

AN - SCOPUS:85100444600

VL - 32

JO - EClinicalMedicine

JF - EClinicalMedicine

SN - 2589-5370

M1 - 100740

ER -